TWI317280B - Method for regulating nutrient absorption with ginsenosides - Google Patents

Method for regulating nutrient absorption with ginsenosides Download PDF

Info

Publication number
TWI317280B
TWI317280B TW95141624A TW95141624A TWI317280B TW I317280 B TWI317280 B TW I317280B TW 95141624 A TW95141624 A TW 95141624A TW 95141624 A TW95141624 A TW 95141624A TW I317280 B TWI317280 B TW I317280B
Authority
TW
Taiwan
Prior art keywords
formula
ginsenoside
rate
compound
ginseng
Prior art date
Application number
TW95141624A
Other languages
Chinese (zh)
Other versions
TW200800231A (en
Inventor
Hang Ching Lin
Tsu Chung Chang
Wen Liang Chang
Hsiou Yu Ding
Tian Shung Wu
Original Assignee
Nuliv Holding Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/426,064 external-priority patent/US20060293255A1/en
Application filed by Nuliv Holding Inc filed Critical Nuliv Holding Inc
Publication of TW200800231A publication Critical patent/TW200800231A/en
Application granted granted Critical
Publication of TWI317280B publication Critical patent/TWI317280B/en

Links

Description

1317280 九、發明說明: 【發明所屬之技術領域】 本發明係提供調節受試者體内營養物質吸收之方法,其包 3才又予有政量由二七參(户如以純化之人 參皂苷化合物,用於調節運送營養物質穿越受試者之腸道細 胞。 【先前技術】 本發明一般係關於用於調節營養物質吸收之方法。 由人類消化系統之研究中,已發現相當多種營養物質可藉 由在胃腸道中分解和消化食物來取得。胃腸道為將食物消化 和吸收之重要路徑。就吸收而言,營養物質,例如葡萄糖、 胺基酸、維生素和其他較小分子,可沿著整個腸道藉由擴散 或藉由特殊運送過程來吸收。而且大部分之此等營養物質可 :由緊密調節機制來運送’取代自由地移經腸道内膜進入血 流或淋巴中。基於目前對於細胞生物學和生理學之理解,營 養物質可利用固著在細胞膜上之特定運送蛋白和通道來運 送。 在葡萄糖運送之實例中,幾乎所有細胞都具有載體介導機 制’以從血液中運送葡萄糖。對大多數細胞來說,該運送係 藉由使用易化葡萄糖轉運體家族中之一或多個葡萄糖轉運體 蛋白(GLUT)之易化擴散作用來進行。在該等案例中,淨葡 萄糖運送之發生係為葡萄糖内向化學梯度之結果。在少數細 胞類型(例如小腸黏m和近側腎小管之細胞)中,來自細胞 卜/谷液之㈣糖攝取可在所謂主動運轉機制中發生抗葡萄糖 5 1317280 中C許來自組織腔室'其葡萄糖濃度可能低於血液 =濃度之葡萄糖淨吸收。有兩種方法,其中能量流可 口運运體偶合。初級主動運輸需要ATP酶提供能量。二級主 =輸提供來自離子流之能量,其係從較高濃度區到:低濃 門根據上述m動運送m離子會結合細胞 2上之運运蛋白而造成運送蛋白之構形改變,其可開啟葡 萄糖之結合位。然後,葙撼Lw β , …俊匍萄糖和運达蛋白結合。與鈉離子(Na+) 和葡萄糖兩者結合之運送蛋白將遭受到進一步之構形改變, 以使咖和納離子⑽進入細胞中。此葡萄糖之主動運 輸涉及鋼離子W)流和葡萄糖流之直接物理偶合,而帶有 衍生來自㈣子(Na+)㈣梯度之過錢量。由於運送事件 包括電核,淨移動(具有非電解質葡萄糖之陽離子鈉(… 離子),該攝取之驅動力包括納離子(Na+)之化學梯度及跨 膜之電位差兩者。當葡萄糖逐漸累積在細胞中,其隨後藉由 易化擴散,經由葡萄糖漢度梯度運出至血液中。同樣… 他營養物質可利用上述運送機制加以吸收。 二七參(户抑打叹/./7处收)已用作傳統中藥,其主要係 用於滋補強化脾臟功能並可增加精力和耐力。根據目前對傳 統中藥的認知,三七參她系萃取自三七參,可幫助腦血管 擴張、增進腦血流量、降低有機體之耗氧量、增進有機體對 缺氧之抗性、降低腦血管阻力、增進有機體之免疫功能、預 Ρ 方出金所k成的中風及提供抗血检、凝血及動脈硬化之功能。 1317280 &然而,三七參尚未用於調節營養物質吸收和運送。而且目 引尚未有卿文或研究專注於使用由中藥(特別是三七參)純化 之皂素(sap0nin)化合物來調節營養物質之吸收。 【發明内容】 於本發明提供調節受試者體内營養物質吸收之方法,其包含 予有效量由二七參(P⑽似”⑽細卿g)純化之人參矣普 化合物’用於調節運送營養物質穿越受試者之腸道細胞。 康本發月之具體實例,係提供用於提高受試者體内營養 物質吸收之古、、i_ 替 彳包含投予有效量由三七參純化之人參皂 ~ 乂驟,用於促進運送營養物質穿越受試者之腸道 細胞。1317280 IX. Description of the invention: [Technical field to which the invention pertains] The present invention provides a method for regulating the absorption of nutrients in a subject, and the package 3 is further administered by a ginseng ginsenoside. a compound for regulating the transport of nutrients across intestinal cells of a subject. [Prior Art] The present invention generally relates to a method for regulating the absorption of nutrients. From the study of the human digestive system, a considerable variety of nutrients have been found. It is obtained by breaking down and digesting food in the gastrointestinal tract. The gastrointestinal tract is an important pathway for digesting and absorbing food. In terms of absorption, nutrients such as glucose, amino acids, vitamins and other smaller molecules can be used along the whole. The intestines are absorbed by diffusion or by special transport processes, and most of these nutrients can be transported by tight regulation mechanisms to replace freely through the intestinal lining into the bloodstream or lymph. Understanding cell biology and physiology, nutrients can be transported using specific transport proteins and channels that are affixed to the cell membrane. In the case of glucose delivery, almost all cells have a vector-mediated mechanism to transport glucose from the blood. For most cells, the transport is by using one or more glucose transporters in the family of facilitated glucose transporters. The facilitated diffusion of body protein (GLUT) is performed. In these cases, the net glucose transport occurs as a result of the inward chemical gradient of glucose. In a few cell types (eg, small intestinal mucosa and proximal tubular cells) In the middle, the sugar uptake from the cell/gu solution can occur in the so-called active mechanism of anti-glucose 5 1317280. C is from the tissue chamber. The glucose concentration may be lower than the net concentration of glucose in the blood concentration. There are two ways. The energy flow is pleasing to the transport body. The primary active transport requires the ATP enzyme to provide energy. The secondary main = transport provides energy from the ion stream, which is from the higher concentration zone to: the low-concentration gate transports the m ion according to the above m Will combine with the transport protein on cell 2 to cause a conformational change in the transport protein, which can open the binding site of glucose. Then, 葙撼Lw β, The combination of Glucosamine and Yunda protein. The carrier protein combined with sodium ion (Na+) and glucose will undergo further conformational changes to allow coffee and nano ions (10) to enter the cell. The direct ionization of the steel ion W) stream and the glucose stream, with the amount of excess derived from the (four) sub (Na+) (four) gradient. Since the transport event includes an electronuclear, net movement (with cationic sodium (... ions) of non-electrolyte glucose, the driving force for this uptake includes both the chemical gradient of nano-ion (Na+) and the potential difference across the membrane. When glucose accumulates in the cell In the middle, it is then transported out to the blood via the gradient of glucose by means of easy diffusion. Similarly, his nutrients can be absorbed by the above-mentioned transport mechanism. The two-seven ginseng (household sighs/./7) Used as a traditional Chinese medicine, it is mainly used to nourish and strengthen the function of the spleen and increase energy and endurance. According to the current knowledge of traditional Chinese medicine, Sanqishen is extracted from Sanqishen, which can help cerebral vasodilation and increase cerebral blood flow. Reduce the oxygen consumption of organisms, increase the resistance of organisms to hypoxia, reduce the cerebral vascular resistance, improve the immune function of organisms, pre-existing strokes and provide anti-blood test, coagulation and arteriosclerosis 1317280 & However, Sanqishen has not been used to regulate the absorption and transport of nutrients. Moreover, there is no Qingwen or research focused on the use of traditional Chinese medicine (special Sanqishen) purified saponin (sap0nin) compound to regulate the absorption of nutrients. [Invention] The present invention provides a method for regulating the absorption of nutrients in a subject, which comprises a pre-effective amount of ginseng (P(10) Like "(10) 细卿g) purified ginseng 矣 化合物 compound 'is used to regulate the transport of nutrients through the intestinal cells of the subject. Kang Benfa's specific example is to provide an increase in the absorption of nutrients in the body of the subject , i_ 彳 彳 彳 彳 彳 彳 彳 彳 彳 彳 彳 彳 彳 彳 彳 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。

5夺根據本發明,係提供用於抑制受試者體内營養物質吸 Η文之方it,"S' 4 X ά, /、匕3投予有效量由三七參純化之人參皂苷化合 守勿之步驟,用^^γ ;减緩運送營養物質穿越受試者之腸道細胞。 根據本發明,人4 . 入參皂苷化合物係由下列組成之群中選出: 弍I之人參I苦Rbl, 7 1317280According to the present invention, a method for inhibiting nutrient absorption in a subject is provided, "S' 4 X ά, /, 匕3 is administered an effective amount of ginsenoside compound purified by Sanqishen. Steps to keep the beat, use ^^γ; slow the transport of nutrients through the intestinal cells of the subject. According to the present invention, the human ginsenoside compound is selected from the group consisting of: 弍I of ginseng I bitter Rbl, 7 1317280

OHOH

式I 式11之人參皂苷Rgi,Ginsenoside Rgi of formula 11

式II 式V之人參急普Ri, 1317280Formula II V of ginseng Ri Ri, 1317280

22 24 ,22 24 ,

式v 式VII之人參皂苷κ,Ginsenoside κ of formula VII,

26 式VII 式VIII之人參皂苷F!, 131728026 Formula VII Ginsenoside F of formula VIII!, 1317280

式III之人參皂苷Rh!,Ginsenoside Rh! of formula III,

或式 IX 之 20(S)-原人參三醇(pr〇t〇panaxatri〇l)。 10 1317280Or 20(S) of formula IX - protopanaxatriol (pr〇t〇panaxatri〇l). 10 1317280

2626

式IX 根據本發明之具體實例,營養 ^ 啊買係包括葡刼糖、胺基酸 或葉酸。特定而言,該胺基酸包括精胺酸和色胺酸。 且可 明 本發明之其他特色和優點將在下列說明中分別提出, 從說明中分別顯見,哎可囍由太欢αα 忒』籍由本發明之實行而得知。本發 之特色和優點將藉由如所述之要 文ι和組合而4到了解及達 成。 應了解前述之發明内容和下列會 _ J貫施方式僅為示例和解釋, 並非為本發明之限制。 【實施方式】 為了更佳了解本發明,水立φ 本文中所使用之術語將另加以詳細 說明。依照藥典之定義, 4苷為任一不同的植物葡萄糖 4 ’虽…、水混合或攪拌時形成4狀料,係用於清潔劑、 起泡劑及乳化劑。人參皂㈣定義為萃取自人參根之三莊皂 素(triterpenoid sap〇nin)化合物 本文令所使用之術語「吸收 久又」你ί曰營養物質經由一條通路 11 1317280 流經小腸上皮細胞而進入血液或淋巴液之攝取。 術扣本文中使用之術語「經純化」係指自粗製或天然形式 分離純化合物或物質之化學過程。術語「腸道細胞」一般: 括腸上皮細胞、黏膜細胞以及負責身體營養物質吸收之:: 上皮細胞。 本發明提供調節受試者體内營養物質吸收之方法,其包含 才又予有政ϊ由三七參純化之人參4苷化合物用於調節運送 營«質穿越受試者之腸道細胞。該方法包含投予受試者有 效量之人參皂苷化合物,用以調節運送營養物質穿越胃腸道 内蚊單層腸道細胞,使得受試者體内營養物質之吸收得到 調郎。投予受試者之有效量的人參息苦化合物係指可在腸道 細胞中維持生存力並增加或抑制運送營養物質穿越腸道細胞 之細胞膜之濃度,且較佳為G.GGu5#M。由於純化自三七參 之人參4#化合物可提高或抑制運送營養物f穿越單層腸 細胞,因此依照所投予之人參息普化合物,該營養物質之吸 收可經調節而維持受試者體内所欲之營養物質吸收量。人參 =化合物可調配成錠劑、藥丸、膠囊和散劑,以〇服_ :有營養物質吸收問題之個體。同時,人㈣化 情況和其他營養因子、添加物、 見 .文疋劑、載劑、結著劑和埴 充刎混合,以製造可用於任何 、 食補充品、飲料和食物。對於4 吸收者之腊 …、S此項技藝者來說顯而易見 的疋,人參㈣化合物可和其他人參妻苦和黃耆阜芽 以雞尾酒方式投予,以對營 勿貝吸收提供協同或累進效 。此外,經純化的人參切化合物亦可由其他中藥植物或 12 K17280 ★本植物來純化’對營養物質吸收功能提供相同之調節效用。 人參皂苷化合物可藉由任何標準方法或此項技藝中已知之 方:或知識來製備。根據本發明,純化自三七參之人參皂苷 物匕括+人參皂苦。該等物質可藉由熟習此項技藝者已知 ㈤萃取和刀冑方法力σ以純化。才艮據本發明之具體實 例’人參皂苷化合物可科 Α _ 』稭由包含下列步驟之方法來製得:磨 碎二七參之根部;以 _ 卒取根°卩物質而產生醇萃取物;分離 亚,、,*二七參根部之醇萃取物,而得釗π # P 4之人表A 普,其包括: 而侍到五種已知之人參皂Formula IX According to a specific example of the present invention, the nutritional system comprises glucosamine, amino acid or folic acid. In particular, the amino acid includes arginine and tryptophan. It is to be understood that the other features and advantages of the invention will be set forth in the description which follows. The features and advantages of the present invention will be understood and achieved by the means and combinations described. It is to be understood that the foregoing summary of the invention and the following aspects of the invention are merely illustrative and illustrative and not restrictive. [Embodiment] For better understanding of the present invention, the terms used herein will be described in detail. According to the definition of the Pharmacopoeia, 4 glycosides are any different plant glucose 4', which is mixed with water to form a 4-shaped material, which is used for detergents, foaming agents and emulsifiers. Ginseng soap (4) is defined as the triterpenoid sap〇nin compound extracted from ginseng root. The term "absorption is long" is used here. You can pass the nutrient through a small intestinal epithelial cell into the blood through a pathway 11 1317280. Or the intake of lymph. The term "purified" as used herein refers to a chemical process that separates a pure compound or substance from crude or natural form. The term "intestinal cells" generally includes: intestinal epithelial cells, mucosal cells, and the absorption of nutrients in the body:: Epithelial cells. The present invention provides a method of modulating the absorption of nutrients in a subject, which comprises the addition of a ginseng 4 glucoside compound purified by Panax notoginseng for regulating the transport of the gut cells of the subject. The method comprises administering to the subject an effective amount of a ginsenoside compound for regulating the transport of nutrients through the monolayer of intestinal cells of the gastrointestinal tract, such that the absorption of nutrients in the subject is conditioned. An effective amount of a ginseng-stable compound administered to a subject means a concentration which can maintain viability in the intestinal cells and increase or inhibit the transport of nutrients through the cells of the intestinal tract, and is preferably G.GGu5#M. Since the ginseng 4# compound purified from the Sanqi ginseng can increase or inhibit the transport of nutrients f through the monolayer of intestinal cells, the absorption of the nutrient can be adjusted to maintain the body of the subject according to the administered ginseng compound. The amount of nutrients absorbed by the body. Ginseng = compound can be formulated into tablets, pills, capsules and powders to sputum _: individuals with nutrient absorption problems. At the same time, human (4) conditions are mixed with other nutrient factors, additives, sputum agents, carriers, binders and sputum to make them suitable for use in any food supplement, beverage and food. For the 4 absorbor's wax ..., S is obvious to the skilled person, the ginseng (4) compound can be administered in a cocktail manner with other ginseng and jaundice buds to provide synergy or progressive effect on the camp. In addition, purified ginseng compounds can also be purified by other Chinese herbal plants or 12 K17280 ★ plants to provide the same regulatory effect on nutrient absorption. The ginsenoside compound can be prepared by any standard method or method known in the art: or knowledge. According to the present invention, ginsenosides from Panax notoginseng are extracted + ginseng soap. Such materials can be purified by the artisan known to those skilled in the art (5) extraction and knife method force σ. According to a specific example of the present invention, the ginseng saponin compound can be obtained by the method comprising the steps of: grinding the root of the ginseng; and extracting the root 卩 substance to produce an alcohol extract; Separating the alcohol extracts from the roots of the sub-, ,, and * ginseng ginseng, and obtaining the 钊π # P 4 person's table A, which includes: and the five known ginseng soaps

ΛΛ

式11之人參皂苷Rgl (以下稱為Ginsenoside Rgl of formula 11 (hereinafter referred to as

Rgi), 13 1317280 hoh2c,Rgi), 13 1317280 hoh2c,

12 HO12 HO

OHOH

式IIFormula II

Rhi)Rhi)

22 24 /VA^/26 23 OH 式111之人參皂苷Rhi (以下稱為22 24 /VA^/26 23 OH ginsenoside Rhi of formula 111 (hereinafter referred to as

2 10 8 3 5 . 7 272 10 8 3 5 . 7 27

式III 式IV之人參皂苷Re(以下稱為Re) 14 1317280Ginsenoside Re of Formula III Formula IV (hereinafter referred to as Re) 14 1317280

式IV 及式V之人參皂苷Ri(以下稱為Ri)。Ginsenoside Ri of formula IV and formula V (hereinafter referred to as Ri).

式V 根據本發明之具體實施例,三七參之醇萃取物可利用吸附 性樹脂、矽膠及逆相層析法加以分離和純化。然後,人參皂 苷Rbi及Rgi可進一步以柚苷酶(naringinase)水解產生代謝 物,其包括 15 1317280 式VI之人參皂苷(以下稱為GF2),Formula V According to a specific embodiment of the present invention, the alcohol extract of Panax notoginseng can be isolated and purified by using an adsorbent resin, tannin extract, and reverse phase chromatography. Then, the ginsenosides Rbi and Rgi can be further hydrolyzed by naringinase to produce a metabolite comprising 15 1317280 ginsenoside of the formula VI (hereinafter referred to as GF2).

式VII之人參皂苷κ(以下稱為CK),Ginsenoside κ of formula VII (hereinafter referred to as CK),

式VI11之人參皂苷F!(以下稱為GFO, 16 I317280Ginsenoside F of formula VI11 (hereinafter referred to as GFO, 16 I317280

及式IX之20(S)-原人參三醇(以下稱為)And IX of the formula IX (S) - the original ginseng triol (hereinafter referred to as)

式IX 由於純化自三七參之人參皂苷化合物可提高或抑制運送營 養物質穿越腸道細胞之細胞膜,因此依照所投予之人參專皆 化合物之群,該營養物質之吸收可經調節而維持個體内所欲 之營養物質吸收量。人參皂苷化合物可調配成錠劑、藥丸、-膠囊和散劑,以口服投予患有營養物質吸收問題或吸收不良 徵候群之個體,其為改變小腸能力’使其得以吸收足夠之營 養物質進入血液中。同時,人參皂苷化合物可視情況和其他 17 1317280 營養因子、添加物、安定劑、載劑、結著劑和填充劑混合, 以製造膳食補充品、飲料、食物和動物飼料。 /本發蝇提供提高受試者體内營養物質吸收之方法,其包含 叙予有效量由二七參純化之人參皂苷化合物之步驟,用於促 進運送營,物、質穿越受試者之腸道細胞。該#養物質包括葡 萄糖、胺基酸或維生素,其中該胺基酸為精胺酸或色胺酸; 該維生素包括葉酸及其他。 根據本發明之具體實例,葡萄糖之吸收係藉由投予濃度從 〇. 001至5//M之人參皂苷化合物來促進運送葡萄糖穿越受試 者腸道細胞而得到提高;其中該人參皂芽化合物包括式【之 扑丨、式VII之CK、式VIII之GF1或式Ιχ之Rga。 根據本發明之具體實例,精胺酸之吸收係藉由投予濃度從 0.001至5#M之人參皂苷化合物來促進運送精胺酸穿越受試 者之腸道細胞而得到提高;其中該人參皂苦化合物包括式【 之w、式π之Rgl、式VII之CK、式Iu之汕、式νπι 之GF1或式IX之Rga。 根據本發明之具體實例,色胺酸之吸收係藉由投予濃度從 至5//Μ之人參皂苦化合物來促進運送色胺酸穿越受試 者之腸道細胞而得到提高;其中該人參皂普化合物包括式 νπ之CK或式IX之Rga。 根據本發明之具體實例’葉酸之吸收係藉由投予濃度從 U01至Μ之人參Μ化合物來促進運送葉酸穿越受試者 之腸道細胞而得到提高;其中該人參I苷化合物包括式νπ 之CK或式I之Rbi。 18 1317280 本發明提供可用於抑制受試者體内營養物質吸 收之方法,包冬於工士 3技予有效量由三七參純化之人參皂苷化合物 之步驟,以減緩 . 碉%運迗營養物質穿越受試者之腸道細胞。該營 養素包括葡萄掩或維生素;其中該維生素包括葉酸及其他。 械本毛月/葡萄糖之吸收係藉由投予濃度從〇. 001至5 U之人參皂苷化合物來減緩運送葡萄糖穿越受試者之腸道 細胞而得到抑制;其中該人參皂*化合物包括式η之Rgl或 式 111 之 Rth。Formula IX Since the ginsenoside compound purified from Panax notoginseng can increase or inhibit the transport of nutrients through the cell membrane of intestinal cells, the absorption of the nutrient can be adjusted to maintain the individual according to the group of ginseng-specific compounds administered. The amount of nutrients absorbed by the body. The ginsenoside compound can be formulated into tablets, pills, capsules and powders for oral administration to individuals suffering from nutrient absorption problems or malabsorption syndromes, which are capable of absorbing enough nutrients to enter the bloodstream. in. At the same time, ginsenoside compounds can be mixed with other 17 1317280 trophic factors, additives, stabilizers, carriers, binders and fillers to make dietary supplements, beverages, food and animal feed. / The present flies provide a method for increasing the absorption of nutrients in a subject, comprising the step of stimulating an effective amount of a ginsenoside compound purified from the ginseng ginseng, for facilitating the transport of the battalion, the passage of matter and quality through the intestine of the subject Road cells. The #养养物 includes glucose, an amino acid or a vitamin, wherein the amino acid is arginine or tryptophan; the vitamin includes folic acid and others. According to a specific embodiment of the present invention, the absorption of glucose is enhanced by administering a ginsenoside compound having a concentration of from 0.001 to 5/M to promote transport of glucose across the intestinal cells of the subject; wherein the ginseng soap compound Included in the formula, CK of formula VII, GF1 of formula VIII or Rga of the formula. According to a specific embodiment of the present invention, the absorption of arginine is enhanced by administering a ginsenoside compound having a concentration of from 0.001 to 5 #M to facilitate delivery of arginine across the intestinal cells of the subject; wherein the ginseng soap The bitter compound includes the formula [w, formula R, CK of formula VII, 式 of formula Iu, GF1 of formula νπι or Rga of formula IX. According to a specific embodiment of the present invention, the absorption of tryptophan is enhanced by administering a ginseng soap compound having a concentration of up to 5//Μ to facilitate delivery of tryptophan acid across the intestinal cells of the subject; wherein the ginseng The soap compound includes CK of the formula νπ or Rga of the formula IX. According to a specific example of the present invention, the absorption of folic acid is improved by administering a ginseng compound having a concentration from U01 to sputum to promote transport of folic acid across the intestinal cells of the subject; wherein the ginseng I glycoside compound comprises the formula νπ CK or Rbi of formula I. 18 1317280 The present invention provides a method for inhibiting the absorption of nutrients in a subject, and the step of using a ginsenoside compound purified by Sanqishen in an effective amount to slow down. Pass through the intestinal cells of the subject. The nutrient includes grape cover or vitamins; the vitamin includes folic acid and others. The dermal honey/glucose absorption is inhibited by administering a ginsenoside compound having a concentration from 〇. 001 to 5 U to slow the transport of glucose through the intestinal cells of the subject; wherein the ginseng soap compound comprises the formula η Rgl or Rth of formula 111.

據本發明,葉酸之吸收係藉由投予濃度從0.001至5//M 窃/皂苷化合物來減緩運送葉酸穿越受試者之腸道細胞而 侍到抑制,其令該人參皂苷化合物包括式11之Rgi或式111 之 Rhi。 根據本發明’葉酸之吸收係藉由投予濃度從0.001至5//Μ 之人參皂苷化合物來減緩運送葉酸穿越受試者之腸道細胞而 得到抑制,其中人參皂苷化合物包括式II之Rgi或式III之 Rh” 本發明更特定地藉由下列實例加以解釋。然而,應了解本 發明不應以任何方式受限於該等實例。 實例1 ·經純化的人參皂苷對葡萄糖吸收之調節效用 細胞培養 為了砰估經純化的人參皂苷化合物對經過小腸腔攝取營養 物質之效用,係將Caco-2細胞放置在可滲透濾臈上生長以作 為實驗模型。Caco-2細胞係取自人類結腸癌並在兩週後同時 19 1317280 分化成類腸上皮細胞表現型。這些細胞形成具有發展良好之 緊密連結之單層,並經詳細評估可作為活體外模型,以用於 研究營養物質和藥物兩者在小腸腔内細胞間之運送。According to the present invention, the absorption of folic acid is inhibited by administering a concentration of from 0.001 to 5//M thief/saponin compound to slow the transport of folic acid across the intestinal cells of the subject, and the ginsenoside compound comprises the formula 11 Rgi or Rhi of formula 111. According to the present invention, the absorption of folic acid is inhibited by administering a ginsenoside compound having a concentration of from 0.001 to 5//Μ to slow the transport of folic acid across the intestinal cells of the subject, wherein the ginsenoside compound comprises Rgi of formula II or Rh of the formula III The invention is more specifically explained by the following examples. However, it should be understood that the invention should not be limited in any way to such examples. Example 1 - Purified ginsenosides regulate the regulation of glucose uptake Culture In order to evaluate the effect of purified ginsenoside compounds on nutrient intake through the small intestine, Caco-2 cells were grown on a permeable filter to serve as an experimental model. Caco-2 cells were obtained from human colon cancer. After two weeks, 19 1317280 differentiated into intestinal epithelial cell phenotypes. These cells form a well-developed, tightly-knitted monolayer that can be evaluated in detail as an in vitro model for studying both nutrients and drugs. Transport between cells in the small intestine.

Caco-2 細胞係取自 ATCC (American Type CultureCaco-2 cell line was taken from ATCC (American Type Culture)

Collection)。將該等細胞放置在Dulbecc〇氏修飾Eagle 培養基(DMEM)中,其含有4.5g/L葡萄糖和25raM之Hepes, 及添加10%胎牛血清、100 υ/mL盤尼西林G和10g/L鏈黴素。 該培養基每兩天更換一次。每個月定期檢查該等細胞之黴漿 菌。將衍生自人類大腸癌之Caco-2細胞株用於供研究藥物在 胃腸道中吸收之活體外模型系統。當將Caco-2細胞培養在半 透膜時,其可分化成具有顯著型態及與小腸柱狀上皮細胞有 生化上相似性之高度功能化上皮細胞屏障。因此caco_2細胞 單層可用於研究多種化合物之膜運送性質。將培養盤以磷酸 緩衝生理食鹽水(PBS )清洗一次,接著加入色胺酸dta 1 〇 分鐘’使細胞色胺酸化。分離出色胺酸化細胞並使用35_ # m 濾網蓋(Falcon 2235 )過濾得到單細胞,之後接種以進行下 一步實驗。 細胞生存力分析 為了偵測經純化的人參皂苷對於Caco-2細胞是否具有毒 性’細胞生存力分析係使用分別添加有丨%和丨〇% FBS之培養 基來進行。將細胞以各孔具有5〇〇〇個細胞之濃度接種在96 孔盤中。為了消除細胞生長之邊際效應,細胞只接種在盤中 間區之60孔中,然而盤周圍區域之36孔中只填充入1〇〇 a i PBS。一旦將細胞置於盤中,將該等細胞培養在含有各種劑量 20 1317280 , 0 2 〇和5 〇 )之經純化的人參皂苷培養基中。三天 後利用3有相同化合物之新鮮培養基替代培養基,並在進 行細胞生存力分析前再培養2天。 細胞生存力係利用細胞計數套組-8 (CCK-8,日本熊本市 Do j i ndo實驗至)分析來測定,該分析係以在具有細胞增生 4 d WST 8之活細胞中NADH之氧化還原反應為基礎。利用脫 氫酶在細胞粒線體之電子還原鏈(ETC)中還原WST-8,而得 到黃色之甲潛(f〇rmazan)產物,其可溶於組織培養基中。 藉由細胞之脫氫酶活性所產生之甲潛染劑之量係和活細胞量 成正比。因此,由ELISA判讀機在波長45〇nm偵測到愈大之 光吸收量’顯示有愈大數量之活細胞。 CCK-8分析係利用在96格式盤之每個孔中加入丨〇 # 1 CCK —8試劑來進行。然後將測定盤蓋上鋁箔紙並在使用elisa 判讀機於波長450nm測量吸收量前再培養兩小時。 葡萄糖攝取分析 將Caco-2細胞(5xl〇4)接種在48-孔盤中並保持在培養 基(含有1 0% FBS、1 %非必需胺基酸、L-麵胺醯胺、盤尼西 林 G(1 00 U/mL)和兩性黴素 B( amphotericin B )(2. 5 /z g/mL) 之DMEM)中於37°c培養i〇天,使細胞分化。每兩天更換一 次培養基。然後以PBS清洗細胞,之後補充含有5% FBS之培 養基及各種濃度(〇.〇1、0.1和1 #M)之純化的人參息苦並 持縯48小時。將Caco-2細胞以PBS將剩餘之葡萄糖洗掉並 在葡萄糖緩衝液(80 mM NaCl、100 ηιΜ甘露醇、2〇 兔緩 衝液-ΗΠ、PH 7.4、3 mM K2HP〇4、1 mM CaCh ' 1 mg/社 bsa) 21 1317280 千敦置1小時。翁益址攻 i4 葡甸糖攝取之起始係利用含有2# Ci/mL之 —— 和未才不疋冷葡萄糖(unlabeled cold glucose ) 之0. 2 ml葡萄糖緩衝液來取代葡萄糖緩衝液,得到最終葡萄 糖/農度為25 mM °藉由移除葡萄糖緩衝液並在指定時間區間 ' β '先來 '冬止葡萄糖攝取。將細胞置於0. 2 mL之0. 2 N ·· · NaOH中办離並將2〇 # L之細胞溶離液轉置至過遽器底之 . Fi 1ter 盤中(Perkim-Elmer,Wei 1 esley,MA,USA)並 於37 C真空洪箱中乾燥。將UniFilter盤底密封並將25以L 之计數溶液加到每個孔中。在封蓋之位置使用具有黏性之盤 黏著劑’且每個樣本之放射性係使用微盤液體閃爍計數器 (TopCount, Packard NXT, Packard BioScience Company, Menden,CT’ USA)加以計算。計算出累積在細胞内之葡萄 糖含量並正常化至蛋白質濃度,且攝取速率係以每分鐘每毫 克細胞蛋白質之奈莫耳葡萄糖(nm〇1/min/mg)來表示。蛋白質 /農度可利用標準二辛可寧酸(Bidnchoninic acid ; BCA )蛋 φ 白質分析來測定。非特定葡萄糖攝取係藉由加入2 # Ci之 ' L_ [ C ]_葡萄糖並從每個測定值中減去來測量,而得到特定 v 葡萄糖攝取量。 葡萄糖吸收分析 就葡萄糖的分析’係將〇, 3 m 1 (105細胞/m 1)之Caco2細胞 接種於各培養室(transwell)之頂室(apical chamber)並於 底室(baso lateral chamber)加入lml的培養基(如上述)。以Collection). The cells were placed in Dulbecc's Modified Eagle Medium (DMEM) containing 4.5 g/L glucose and 25 raM Hepes, plus 10% fetal bovine serum, 100 υ/mL penicillin G, and 10 g/L streptomycin. . The medium was changed every two days. The mycelium of these cells is regularly inspected every month. A Caco-2 cell line derived from human colorectal cancer was used for an in vitro model system for the absorption of the study drug in the gastrointestinal tract. When Caco-2 cells are cultured in a semi-permeable membrane, they can differentiate into highly functionalized epithelial cell barriers with significant conformation and biochemical similarity to small intestinal columnar epithelial cells. Therefore, a single layer of caco_2 cells can be used to study the membrane transport properties of various compounds. The plate was washed once with phosphate buffered saline (PBS), followed by the addition of tryptophan dta 1 〇 minutes to acidify the cells. The excellent alanated cells were isolated and filtered using a 35_#m filter cover (Falcon 2235) to obtain single cells, which were then inoculated for the next experiment. Cell viability assay To determine whether purified ginsenosides are toxic to Caco-2 cells, cell viability assays were performed using medium supplemented with 丨% and 丨〇% FBS, respectively. The cells were seeded in a 96-well plate at a concentration of 5 cells per well. In order to eliminate the marginal effect of cell growth, cells were seeded only in 60 wells in the middle of the disc, whereas only 36 μl of i PBS was filled into the 36 wells in the area around the disc. Once the cells were placed in a dish, the cells were cultured in purified ginsenoside medium containing various doses of 20 1317280, 0 2 〇 and 5 〇). Three days later, the medium was replaced with 3 fresh medium having the same compound, and cultured for another 2 days before cell viability analysis. Cell viability was determined by analysis of Cell Counting Set-8 (CCK-8, Do ji ndo, Kumamoto, Japan), which was a redox reaction of NADH in living cells with 4 d of WST 8 cells. Based on. The dehydrogenase is used to reduce WST-8 in the electron reduction chain (ETC) of the cell mitochondria to obtain a yellow product of the m〇rmazan which is soluble in the tissue culture medium. The amount of a latent dye produced by the dehydrogenase activity of the cells is directly proportional to the amount of viable cells. Therefore, the larger the amount of light absorption detected by the ELISA reader at a wavelength of 45 〇 nm, indicates that a larger number of living cells are present. CCK-8 analysis was performed by adding 丨〇 # 1 CCK-8 reagent to each well of a 96 format disk. The assay pan was then covered with aluminum foil and incubated for an additional two hours before measuring the absorbance at 450 nm using an elisa reader. Glucose Uptake Analysis Caco-2 cells (5xl〇4) were seeded in a 48-well plate and maintained in medium (containing 10% FBS, 1% non-essential amino acid, L- faceamine, penicillin G (1) 00 U/mL) and amphotericin B (2.5/zg/mL) in DMEM) were cultured at 37 ° C for differentiation. The medium was changed every two days. The cells were then washed with PBS, and then supplemented with 5% FBS medium and purified ginseng at various concentrations (〇.〇1, 0.1, and 1#M) for 48 hours. Caco-2 cells were washed away with PBS in PBS and buffered in glucose buffer (80 mM NaCl, 100 ηι mannitol, 2 〇 rabbit buffer-ΗΠ, pH 7.4, 3 mM K2HP〇4, 1 mM CaCh ' 1 Mg / society bsa) 21 1317280 thousand for 1 hour. Wengyi site attacked i4. The beginning of the glucose uptake was replaced with 0.2% of glucose buffer containing 2# Ci/mL and unlabeled cold glucose. The final glucose/agriculture level was 25 mM ° by removing the glucose buffer and starting the 'β' for the specified time interval to stop the glucose uptake. Place the cells in 0. 2 mL of 0.2 N ·· · NaOH and transfer the 2 〇 # L cell lysate to the bottom of the filter. Fi 1ter plate (Perkim-Elmer, Wei 1 Esley, MA, USA) and dried in a 37 C vacuum chamber. The UniFilter disc bottom was sealed and 25 count solutions of L were added to each well. A viscous disc adhesive was used at the location of the closure and the radioactivity of each sample was calculated using a microdisc liquid scintillation counter (TopCount, Packard NXT, Packard BioScience Company, Menden, CT' USA). The glucose content accumulated in the cells was calculated and normalized to the protein concentration, and the uptake rate was expressed as nanomolar glucose (nm〇1/min/mg) per milligram of cellular protein per minute. Protein/agriculturality can be determined using standard bicinchoninic acid (BCA) egg φ white matter analysis. Non-specific glucose uptake was measured by adding 2 # Ci's 'L_[C]_glucose and subtracted from each measured value to obtain a specific v glucose uptake. Glucose uptake analysis for the analysis of glucose' is to inoculate 3 m 1 (105 cells/m 1 ) of Caco 2 cells in the apical chamber of each transwell and add in the baso lateral chamber. Lml of medium (as described above). Take

Costar 培養室插片(No. 3414,Corning Incorporated, NY, USA)將24-孔盤之各孔分離成頂室(定義為插片上方之小室) 22 1317280 及底室(定義為插片下方之小室)。每隔二天更換各培養室之 頂室和底室中之培養基。為了確定培養室中形成的Caco2單 層胞臈之緊密結合完整性,係使用Milliceii®-ERS (Millipore EV0M-6; World Precision Instrument,Costar culture chamber inserts (No. 3414, Corning Incorporated, NY, USA) separated the wells of the 24-well plate into a top chamber (defined as a chamber above the insert) 22 1317280 and a bottom chamber (defined as under the insert) small room). The medium in the top and bottom chambers of each culture chamber was changed every two days. To determine the tight binding integrity of Caco2 monolayers formed in the culture chamber, Milliceii®-ERS (Millipore EV0M-6; World Precision Instrument,

Sarasota,FL,USA)進行轉運上皮電阻(Trans-EpithelialSarasota, FL, USA) Transit Epithelial Resistance (Trans-Epithelial)

Electrical Resistance)(TEER)分析以測量介於培養室之頂 至和底室間之TEER。當測量的TEER到達300至450 Ω cm2 於培養的14至21天在細胞底側具有分化的刷狀緣存在時, 則4 Caco2單層已準備好可進行葡萄糖吸收試驗。取得各實 驗岫、實驗中及實驗後之TEER值,以驗證所收集數據之一致 性。 在葡萄糖吸收分析中,Cac〇2細胞單層係以含有5%1?以及 經純化各種濃度(1、ο·1及0.01 “)之人參皂苷之培養基 預先處理2天’之後將CaeG2細胞單層進—步置於葡萄糖吸 收緩衝液⑽ Nacl、100 mM mannit0 卜 20 mM Tris_Hcl、 PH 7. 4 ' 3 mM K2HP〇4、1 mM CaCh、i 邶胤 BSA)中培養 i 小時。葡萄糖吸收之起始係利用新鮮的葡萄糖吸收緩衝液替 代底室及以含有2//Ci/mT n「Hi 之 D-[ c]-葡萄糖(60 Ci/mmol,Electrical Resistance) (TEER) analysis to measure TEER between the top of the chamber and the bottom chamber. When the measured TEER reached 300 to 450 Ω cm2 in the presence of a differentiated brush border on the bottom side of the culture for 14 to 21 days of culture, the 4 Caco2 monolayer was ready for glucose uptake assay. TEER values were obtained for each experiment, experiment, and post-experiment to verify the consistency of the collected data. In the glucose uptake assay, the Cac〇2 cell monolayer was pretreated with 5% 1? and pre-treated for 2 days after purification of various concentrations (1, ο, 1 and 0.01") of ginsenosides. The reaction was carried out for 1 hour in glucose uptake buffer (10) Nacl, 100 mM mannit0, 20 mM Tris_Hcl, pH 7. 4 '3 mM K2HP〇4, 1 mM CaCh, i 邶胤BSA). Replacing the bottom chamber with fresh glucose absorption buffer and D-[c]-glucose (60 Ci/mmol, containing 2//Ci/mT n "Hi,

American RadiolabeleH ,American RadiolabeleH,

Deled Chemicals, ARC, St. Louis, MO, USA)和未標定的冷葡葙播, (unlabeled cold glucose)之 〇. 2 m 1葡萄糖緩衝液來替代頂它>θ — 代員至’传到最終葡萄糖濃度為25 mM。 母隔5或10分鐘區間由頂— 至取連續五個10-"L樣本。抽取 樣本後將相同量之樣本繮衝 、、衝液加回底室中,以維持一定的緩 衝液體積。將樣本轉置於禍。 、匕’慮益底之UniFi 1 ter盤中 23 1317280 (Perkim-Elmer,Wellesley,MA,USA)並於 37t:真空烘箱 中乾燥。將Uni Filter盤底密封並將25 # L之計數溶液加 到各孔中。在封蓋之位置使用具有黏性之盤黏著劑,且每個 樣本之放射性係使用微盤液體閃爍計數器(T〇pC〇unt, Packard NXT, Packard BioScience Company, Meriden, CT USA )加以計鼻。試驗化合物對葡萄糖吸收之效用係以相對時 間(分鐘)累積在底室之葡萄糖奈莫耳數(nm〇1/rain)來表示。 葡萄糖吸收速率係藉由計算從時間零開始至各圖之圖形數據 的終點之直線斜率所得到的。非特定葡萄糖攝取係藉由加入 2//Ci之L-[14C]-葡萄糖並從每個測定值中減去來測量,而 得到特定攝取量。 在細胞生存力分析中,在含有丨〇% FBS的培養基中濃度從 〇. 1至_i〇#M之經純化的人參皂苷對Caco2細胞不具有毒 性。然而在含有1% FBS的培養基十濃度10至5MM之 對Cac〇2細胞則展現了細胞毒性。因此,經純化的人參皂苷 在後續實驗中係以不會對細胞之生存力和形態學有反向效用 之濃度範圍下投予。較佳地,經純化的人參皂苷係以從〇 至0.5//M之濃度範圍投予。 由表1所示之葡萄糖吸收分析結果,已發現經純化的人參 皂普例如式mbl、式VIIUK、式π之以、式⑴之 Rhi、式α V111之GF丨或式! χ之Rga對於運送葡萄糖穿越 細胞單層具有調節效用。亦即,經純化的人參W增進或抑 制:越Cac〇2細胞單層之葡萄糖運送。葡萄糖之運送速率經 计异係為代表以測量培養室之底室中葡萄糖總量相對時 24 1317280 間(分鐘)之曲線梯度。關於圖卜當Cac〇2細胞經滚产〇 ] 至之式1 .處理,則葡萄糖運送速率增加。又 另一方面,如表1所千 ^所不’兩種經純化的人參息芽式Deled Chemicals, ARC, St. Louis, MO, USA) and uncalibrated cold-labeled cold glucose (unlabeled cold glucose). 2 m 1 glucose buffer instead of top it>θ - generation to 'pass The final glucose concentration was 25 mM. The parent interval is from 5 to 10 minutes from the top to the last five 10-"L samples. After the sample is taken, the same amount of sample is buffered and flushed back into the bottom chamber to maintain a certain buffer volume. Turn the sample into trouble. In the UniFi 1 ter pan 23 1317280 (Perkim-Elmer, Wellesley, MA, USA), dry at 37t: vacuum oven. The Uni Filter pan was sealed and 25 # L of the counting solution was added to each well. A viscous disk adhesive was used at the location of the closure, and the radioactivity of each sample was counted using a microplate liquid scintillation counter (T〇pC〇unt, Packard NXT, Packard BioScience Company, Meriden, CT USA). The effect of the test compound on glucose uptake is expressed as the number of glucose nanomoles (nm〇1/rain) accumulated in the base at relative time (minutes). The glucose absorption rate is obtained by calculating the slope of the straight line from the time zero to the end point of the graphic data of each graph. Non-specific glucose uptake was measured by adding 2//Ci of L-[14C]-glucose and subtracted from each measurement to obtain a specific uptake. In the cell viability assay, purified ginsenosides at concentrations ranging from 〇.1 to _i〇#M in culture medium containing 丨〇% FBS were not toxic to Caco2 cells. However, Cac〇2 cells exhibited a cytotoxicity in a medium containing 10% to 5 mm of a medium containing 1% FBS. Therefore, the purified ginsenoside was administered in a subsequent concentration range which did not adversely affect the viability and morphology of the cells. Preferably, the purified ginsenoside is administered at a concentration ranging from 〇 to 0.5//M. From the results of the glucose uptake analysis shown in Table 1, it has been found that the purified ginseng is, for example, of the formula mbl, the formula VIIUK, the formula π, the Rhi of the formula (1), the GF丨 of the formula α V111 or the formula! Rga has a regulating effect on transporting glucose across cell monolayers. That is, the purified ginseng W promotes or inhibits: the more the Cac〇2 cell monolayer is transported by glucose. The glucose transport rate is calculated as a representative curve to measure the gradient of the total amount of glucose in the bottom chamber of the culture chamber relative to 24 1317280 (minutes). Regarding the treatment of the Cac〇2 cells in the Tubu], the glucose transport rate was increased. On the other hand, as shown in Table 1, the two purified ginseng buds

Rgi及式111之Rhi兩者均顯干科^ aRgi and Rhi of formula 111 are both dry and dry

^ 0 构顯不對葡萄糖吸收有抑制效用。M^ 0 The structure does not have an inhibitory effect on glucose absorption. M

當CaC〇2細胞單層經濃度。.01至之式n R 處:,則葡萄糖運送明顯的受到抑制 '經純化 ;; ^葡萄糖穿過_2細胞單層之卿效用係肋下表相 二==上代表對葡萄糖運送具提高效用,而箭頭朝 下代表對葡萄糖運送具抑制效用。 •經純化的人參東接料站结此栉卞·用When the CaC〇2 cells were monolayer in concentration. .01 to the formula n R :, then the glucose transport is obviously inhibited 'purified; ^ ^ glucose through the _2 cell monolayer of the effect of the ribs of the table below the second == upper represents the effectiveness of the glucose transporter While the arrow pointing down represents the inhibitory effect on the glucose transporter. • The purified ginseng east receiving station is used for this purpose.

控制組 DU X 0 1 4 土 0.0584 100 - K Di 1 3. 4250 土 0. 4805 157. 01 个 0. 1 2. 8107 土 0. 1982 128,85 个 ......*.— 0. 01 2. 2306 土 0. 1034 102. 26 个 CK -· ------,- 1 2. 9008 士 0. 2184 132.98 个 0. 1 2. 8689 士 0.2783 131.52 个 0. 01 3. 3164 士 0. 1911 152.03 个 Rgi 1 2. 1089 土 0.2097 96. 68 Ψ 0. 1 1. 2763 土 0. 1907 58. 51 Φ ------ 0. 01 1. 1317 + 0. 1299 51. 88 Φ Rhi — 1 1. 3310 士 0. 8356 61. 02 Φ ——— —_ 0. 1 1. 6329 土 0. 1976 74. 86 Φ 25 1317280 0. 01 1.3568 土 0.1090 62. 20 Φ GF1 1 3.2862 土 0.3429 150. 65 个 0. 1 3.3551 土 0.3248 153.80 个 0. 01 3.0783 土 0.9550 141. 12 个 Rga 1 2.2689 土 0.2598 104. 01 个 0. 1 3.6462 土 0.4105 167. 15 个 0.01 2.5454 土 0.7808 116. 69 个 因此’結論是葡萄糖之吸收可利用投予由三七參純化之人 參皂苷’式I之Rbi、式II之Rgi、式VII之CK、式III之 Rh!、式VIII之GF1或式IX之Rga來調節。 實例2 :經純化的人參皂苷對精胺酸吸收之調節效用 精胺酸吸收分析 在測量精胺酸穿越Caco2細胞單層之運送中,將培養室 (transwells)之兩側以包含 137 ㈣ NaC1、1〇 ㈣ 、 0. 3 mM NaH2P〇4、〇. 3 mM K2Hp〇4、5. 4 mM κπ、2. 8 滷 、 1 mM MgS〇4、l〇 mM葡萄糖,調整至邱值7 4之精胺酸培養 缓衝液清洗。然後,將細胞層放置在培養緩衝液中在37乞下 預培養1小時。頂室(apical i chamber)和底室(bas〇iateral chamber)中培養緩衝液之體積分別為〇. 2和〇. 9 η。在進 行運送實驗前,將兩室中之細胞以新鮮培養基替代。運送實 驗之起始係藉由含有10inML_精胺酸之溶液(其中包含 #Ci/mL之L-⑺一精胺酸)替代頂側之培養溶液。在指定時 26 1317280 間區間,將丨0 # L_溶液樣本從底側移除並使用微盤液體閃 爍計數器(TopCount,PackardNXT)計算各樣本之放射性。 使用[3H]-甘露醇之攝取校正分子穿過單層膜之非特定運 迗。結果係以相對時間(分鐘)運送精胺酸穿越Cac〇_2細胞單 層之奈莫耳數(nmo 1/m i η )來表示。 由表2令所示之精胺酸吸收分析結果,已發現經純化的人 參皂苷,式I之Rbl、式ΠΙ之CK、式丨丨之^、式ΙΠ之 壯1式VIII之GF1或式IX之Rga,對運送精胺酸穿越Cac〇2 細胞單層具有調節效用。經純化的人參㈣對—Μ細胞中 精胺酸運送之調節效用係列於下表2令,其中箭頭朝上代表 對精胺酸運送具提高效用。 養_2 :經純化的人參皂普對精胺酸運镁夕姻節效用 化合物(# Μ) 運送速率( nmol/min) ± 對照組 10.6855 土 0.2523 刀 PU V 7〇 ^ 100 CK 1 14.1530 士 0. 9315 132.45 个 0. 1 14.9247 土 1.4850 139. 67 个 0.01 12.8943 土 0. 3197 120.67 个 Rbi 1 16.1484 土 0.6228 151.12 个 0. 1 11.8699 ± 1.9300 111.08 个 0. 01 9.6487 土 0.9377 90. 30 Rhi 1 14.3209 土 0.7418 134.02 个 0. 1 11.6615 土 0.8085 109.13 个 0. 01 11.2792 土 0.7768 105.56 个 Rgi 1 18.3265 士 0. 8965 171.51 个 27 1317280 GFlControl group DU X 0 1 4 soil 0.0584 100 - K Di 1 3. 4250 soil 0. 4805 157. 01 0. 1 2. 8107 soil 0. 1982 128,85 ..... 01 2. 2306 0. 1034 102. 26 CK -· ------, - 1 2. 9008 士 0. 2184 132.98 0. 1 2. 8689 士 0.2783 131.52 0. 01 3. 3164 士士0. 1911 152.03 Rgi 1 2. 1089 Soil 0.2097 96. 68 Ψ 0. 1 1. 2763 Earth 0. 1907 58. 51 Φ ------ 0. 01 1. 1317 + 0. 1299 51. 88 Φ Rhi — 1 1. 3310 ± 0. 8356 61. 02 Φ ——— —_ 0. 1 1. 6329 Soil 0. 1976 74. 86 Φ 25 1317280 0. 01 1.3568 Soil 0.1090 62. 20 Φ GF1 1 3.2862 Soil 0.3429 150. 65 0. 1 3.3551 Soil 0.3248 153.80 0. 01 3.0783 Soil 0.9550 141. 12 Rga 1 2.2689 Earth 0.2598 104. 01 0. 1 3.6462 Soil 0.4105 167. 15 0.01 2.5454 Soil 0.7808 116. 69 'Conclusion that the absorption of glucose can be applied to Rbi, which is purified by Panax notoginseng, Rbi of formula I, Rgi of formula II, CK of formula VII, Rh! of formula III, GF1 of formula VIII or Rga of formula IX. Adjustment. Example 2: Regulating effect of purified ginsenoside on arginine absorption arginine absorption analysis In measuring the transport of arginine across the Caco2 cell monolayer, the sides of the transwells were included to contain 137 (tetra) NaC1 1〇(4), 0. 3 mM NaH2P〇4, 〇. 3 mM K2Hp〇4, 5. 4 mM κπ, 2.8 Halogen, 1 mM MgS〇4, l〇mM glucose, adjusted to a value of 7 7 Amino acid culture buffer wash. Then, the cell layer was placed in a culture buffer and precultured at 37 Torr for 1 hour. The volume of the culture buffer in the apical i chamber and the bas〇iateral chamber is 〇. 2 and 〇. 9 η, respectively. The cells in both chambers were replaced with fresh medium before the transport experiments. The start of the transport experiment was replaced by a solution containing 10 inML_arginine, which contained #Ci/mL of L-(7)-arginine. At the time specified, between 26 1317280, the 丨0 #L_ solution sample was removed from the bottom side and the radioactivity of each sample was calculated using a microdisk liquid scintillation counter (TopCount, Packard NXT). The non-specific operation of the molecules through the monolayer is corrected using the uptake of [3H]-mannitol. The results are expressed in terms of the relative time (minutes) of transporting arginine across the monolayer of Cac〇 2 cell monolayer (nmo 1/m i η ). From the results of arginine absorption analysis shown in Table 2, it has been found that purified ginsenoside, Rbl of formula I, CK of formula 、, 丨丨 of formula 、, GF1 of formula VIII or formula IX Rga has a regulatory effect on transporting arginine across a single layer of Cac〇2 cells. The effect of the purified ginseng (IV) on the regulation of arginine transport in the sputum cells is shown in Table 2 below, with the arrow pointing upwards representing an increase in the effectiveness of the arginine transporter.养_2: Purified ginseng saponin to arginine magnesium granules compound compound (# Μ) transport rate (nmol/min) ± control group 10.6855 soil 0.2523 knife PU V 7〇^ 100 CK 1 14.1530 士0 9315 132.45 0. 1 14.9247 Earth 1.4850 139. 67 0.01 12.8943 Earth 0. 3197 120.67 Rbi 1 16.1484 Soil 0.6228 151.12 0. 1 11.8699 ± 1.9300 111.08 0. 01 9.6487 Earth 0.9377 90. 30 Rhi 1 14.3209 0.7418 134.02 0. 1 11.6615 Soil 0.8085 109.13 0. 01 11.2792 Soil 0.7768 105.56 Rgi 1 18.3265 ± 0. 8965 171.51 27 1317280 GFl

Rga 〇. 1 22. 5370 ± 〇· 8912 〇.01 13.5583 ± Umo 1 1〇-37H ± 0.6574 °- 1 12.6865 ± 0.2964 0.0113.5425 ± 1 l〇. 1 920 ± 1. 2390 °* 1 !〇· 7555 + 〇> 4532 0.〇l 12.6265 ± 0.9875 210. 91 126.89 97. 06 118.73 126.74 95. 38 100. 118. 七參純化 个 个 个 个 66 16 个 人參皂 “疋精胺酸之吸收可利用投予由三…化之 包括式…131、式11之化、式、式⑴之以 式VUI之GF1或式IX之Rga來調節 實例3、.二純化的人參皂苷對色胺酸吸收之調節效用 色胺酸吸收分析Rga 〇. 1 22. 5370 ± 〇· 8912 〇.01 13.5583 ± Umo 1 1〇-37H ± 0.6574 °- 1 12.6865 ± 0.2964 0.0113.5425 ± 1 l〇. 1 920 ± 1. 2390 °* 1 !〇· 7555 + 〇> 4532 0.〇l 12.6265 ± 0.9875 210. 91 126.89 97. 06 118.73 126.74 95. 38 100. 118. Seven ginseng purified ones 66 16 ginseng soap "Ammonia arginine absorption available The regulation of the absorption of tryptophan by the ginseng saponin of Example 3, the purified ginsenoside by the GF1 of the formula VUI or the Rga of the formula IX by the formula (131), the formula, the formula (1) Utility tryptophan absorption analysis

除了使用3有137 mM氣化膽驗、10 mM Hepes、0. 6 mM p〇4 5’ 4 mM KC1、2. 8 mM CaCl2、1 mM MgS〇4 和 1〇 遞 萄搪之色胺酸培養緩衝液,並使其时值調整至Η外,係 二類似於實例2中之實驗程序來測量色胺酸分子穿過Cac〇 攝取。結果以相對時間(分鐘)運送色胺酸穿越—0-2 細胞單層之奈莫耳數“—)來表示。 夂 中所不之色胺酸吸收分析結果,已發現經純化的, 苷例如式VI1之CK及式11之Rg!,對於運送精胺酸: ac。2細胞單層具有調節效用。亦即,經純化的人參皂: 28 1317280 j曰進運送精胺酸穿越C:aco2細胞單層。關於圖4,當Cac〇2 ::胞早層以濃度從Ul至〇· 1 " Μ之式VII CK處理,則色胺 "運I速率增加。如表3中所示,當細胞單層以濃度 "〇. 〇 01至〇. 1从Μ之式π I Rgi處理,則色胺酸運送速率增 加。經純化的人參皂苦對運送色胺酸穿越Caco2細胞單層之 调節效用係列於下表3中。 A_3:經純化的人n讧挪色胺酸運送之調節敎用— __是生_速率(nmol/HiirO 百分比(Qy^ 對照组 12.430 ± 0.8103 1〇〇 _ CK 〇, 1 18·〇5〇 ± 0.5557 145.21 个 〇, 01 13-〇5〇 ± 0.5655 104.99 个 〇. 1 17.71〇 ± 0.5948 142.48 个 133.47 个In addition to the use of 3 137 mM gasification test, 10 mM Hepes, 0.6 mM p〇4 5' 4 mM KC1, 2.8 mM CaCl2, 1 mM MgS〇4 and 1 〇 搪 搪 tryptophan culture The buffer was adjusted to the outside of the buffer and the experimental procedure in Example 2 was used to measure the uptake of tryptophan molecules through Cac. The results are expressed in terms of the relative time (minutes) of transporting tryptophan through the -2-2 cell monolayer of the nemesis "-". The results of the tryptophan absorption analysis in the sputum have been found to be purified, for example, glycosides. CK of formula VI1 and Rg! of formula 11 have a regulating effect on transporting arginine: ac. 2 cell monolayer. That is, purified ginseng soap: 28 1317280 j delivers arginine across C: aco2 cells Single layer. With respect to Figure 4, when the Cac〇2:-cell front layer was treated with a concentration from Ul to 〇·1 " 式 VII CK, the tryptamine "I rate increased. As shown in Table 3, When the cell monolayer is treated at a concentration of "〇. 〇01 to 〇. 1 from the formula π I Rgi, the tryptophan transport rate is increased. Purified ginseng soap is used to transport tryptophan across the Caco2 cell monolayer The regulatory utility series is shown in Table 3. A_3: Purified human n讧 讧 胺 运送 之 — — — — _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ CK 〇, 1 18·〇5〇± 0.5557 145.21 〇, 01 13-〇5〇± 0.5655 104.99 〇. 1 17.71〇± 0.5948 142.48 133 .47

Rgl °· 01 1 6.590 + 1.41 90 .16,.180 ± 2.8700 ΐ.^π 17 0. 001 結論是色胺酸之吸收可利用投予由三七參純化之人參了 苷,包括式II之Rgl或式VII之CK來調節。 實例4 ··經純化的人參皂㈣葉酸攝取之調節效用 葉酸攝取分析 將CaC〇2細胞以類似上列實例1葡萄糖攝取分析中所描述 之方法進行葉酸攝取試驗。在葉酸攝取試驗t,以含有5%m 和漠度…Μ經純化的人參皂*之培養基,將一細胞預 處理2天,之後將細胞置於葉酸攝取緩衝私❹㈣“Μ 29 !317280Rgl °· 01 1 6.590 + 1.41 90 .16,.180 ± 2.8700 ΐ.^π 17 0. 001 The conclusion is that the absorption of tryptophan can be administered to the ginseng purified by Panax notoginseng, including Rgl of formula II. Or CK of formula VII to adjust. Example 4 · Adjusted effect of purified ginseng soap (tetra) folate uptake Folic acid uptake assay CaC〇2 cells were subjected to a folate uptake assay in a manner similar to that described in the Glucose uptake assay of Example 1 above. In the folic acid uptake test t, one cell was pretreated for 2 days in a medium containing 5% m and indifferent... purified ginseng soap*, and then the cells were placed in a folic acid uptake buffer (4) "Μ 29 !317280

LaCl2、0. 1 g/L MgCl2 和 0. 1 g/L MgS〇P PH6. 0 之 Hank 氏平 衡鹽溶液)培養1小時。然後開始吸取緩衝液,且攝取之起 始係藉由加入含有2// Ci/mL放射性葉酸(3, 5, 7, 9-3H-葉酸, 25 mCi/mraol,ARC))及冷的未標定葉酸之〇 2 ml新鮮葉酸 攝取緩衝液,得到5 # Μ最終濃度之葉酸。指定時間區間移除 -攝取緩衝液終止攝取。然後以冰冷的PBS清洗細胞三次並加 .入0· 2mL之0. 2Ν NaOH使細胞溶解,接著於65ac培養2〇分 鐘。3H-葉酸之細胞間攝取係利用將2〇 # L細胞溶解液轉移 至過濾器底之UniFilter盤(perkiin-Elmer)並如前面實例 1中所述計數來測定。計算出葉酸累積在細胞内之量並正常 化至蛋白質濃度,而攝取速率係以每分鐘每毫克細胞蛋白質 中之皮可莫耳(picom〇les)(pm〇1/min/rag)來表示。蛋白質 濃度係利用上述之標準二辛可寧酸(Bicinch〇ninic狀“; BCA )蛋白質分析來測定。 關於圖5及表4,以濃度〇」之式VU^CK或式!之 Rb!處理之Caco2細胞,經發現展現出比具有未處理q⑶一2 細胞之對照組較高之葉酸攝取。相反的,如表4所示,以濃 度的式UiRgl或式Iu之Rhi處理之Cac〇2細胞具 有較低的葉酸攝取。經純化的人參息㈣Ca.2細胞内葉酸 攝取之=效用係列於下表4中,其中箭頭朝上代表對葉酸 攝取具提高效用,而箭頭朝上代㈣葉酸攝取具抑制效用。 一4:經純化的人參皂苷對葉酸攝取之調節教用LaCl2, 0.1 g/L MgCl2 and 0.1 g/L MgS〇P PH6. 0 in Hank's balanced salt solution) were incubated for 1 hour. Then the buffer was started and the ingestion was initiated by adding 2// Ci/mL of radioactive folic acid (3, 5, 7, 9-3H-folate, 25 mCi/mraol, ARC) and cold uncalibrated. Folic acid in 2 ml of fresh folic acid uptake buffer to obtain a final concentration of folic acid at 5 #Μ. Specified time interval removal - Ingestion buffer to stop ingestion. The cells were then washed three times with ice-cold PBS and added to 0. 2 mL of 0.2 NaOH to dissolve the cells, followed by incubation at 65 ac for 2 Torr. The intercellular uptake of 3H-folate was determined by transferring the 2 〇 # L cell lysate to a UniFilter disk (perkiin-Elmer) at the bottom of the filter and counting as described in Example 1 above. The amount of folic acid accumulated in the cells was calculated and normalized to the protein concentration, and the rate of uptake was expressed as picom〇les (pm〇1/min/rag) per milligram of cellular protein per minute. The protein concentration was determined by the above-mentioned standard bicinchoninic acid (Bicinch〇ninic-like) (BCA) protein analysis. With respect to Fig. 5 and Table 4, the concentration 〇" is VU^CK or formula! The Rb! treated Caco2 cells were found to exhibit higher folate uptake than the control group with untreated q(3)-2 cells. In contrast, as shown in Table 4, Cac〇2 cells treated with the concentration of UiRgl or Rhi of the formula Iu had lower folate uptake. Purified human ginseng (IV) Ca.2 intracellular folate uptake = utility series is shown in Table 4 below, with the arrow pointing upwards indicating an increased effect on folate uptake, while the arrow up to the top (4) folate uptake has inhibitory effects. A4: Purified ginsenosides regulate the regulation of folic acid uptake

30 1317280 0, 1 M CK 對照組 0. 1 M Rbi -763(L±_3. 206 !·7210 + 0>1611 0. 0320 148.55 个 100 _ 108.72 t 對照組 0. 1 M Rhi 7210 ± 0.1611 453 L 7210 ± 0.1611 —〇78Q ^ Π 1^/1 100 „ 49.36 ; 對照組 0. 1 M Rgi 100 _ _ 62.64 4 結論是葉酸之攝取可利用投予由三七參純化7人參皂|厂 包括式I之版、式II之Rgi、式vn之CK或式ΠΙ之肋1 來調節。 儘官上列實例描述了調節大腸癌細胞之營養物質吸收,但 應了解本發明並不 < 限於此。只要腸道細胞和胃腸系統之細 胞具有相似之營養物質運送機帝!,這些細胞亦預期可從本發 明提出之人參皂苷化合物之調節效用中得到利益。而且本發 明所述之人參皂苷除了在葡萄糖和葉酸吸收中扮演調節角色 外,其同樣可應用於調節營養物質(包括維生素、胺基酸、荷 爾蒙、生長因子及其他細胞代謝之重要元素)之吸收。再者, 具體實例中所描述之營養物質吸收試驗和營養物質攝取試驗 可相互交換施行,用於評定和評估本發明經純化的人參皂苷 對個人營養物質吸收之調節效用。 热習此項技藝者應了解,在不悖離其廣泛的發明概念下, 上述具體實例可做改變。因此應了解,本發明並不受限於本 文中所揭示之特定具體實例,但係希望將該等修正涵蓋在如 所附的申請專利範圍定義之本發明的精神和範缚内。 31 1317280 【圖式簡單說明】 當結合所附的圖式 、閲5責Η守,將更能了解前述之發明内容以 下列實施方式。被七 /τ ^ 洗说明本發明之目的而言,在圖式具體實 例中所顯示的,苴為 a 八两9刚較佳之說明。然而應了解,本發明 並不限於所示之嚴謹的安排和工具。 . 在圖中: ' 為泰$圖,係顯示當Caco2單層細胞以經選擇濃度之 1 ^化的人參皂苦队處理時,於運送穿越底室所測 量之葡萄糖吸收速率; 為線形圖,係顯示當Caco2單層以經選擇濃度之式11 士化的人參皂苷Rgl處理時,於Sink運送穿越底室所測量之 葡萄糖吸收速率; .圖3為線形圖,係顯示當Caco2單層以經選擇濃度之式! j 純化的人參皂苦Rgl處理時,於Sink運送穿越底室所測量之 精胺酸吸收速率; > 圖4為線形圖,係顯示當Cac〇2單層以經選擇濃度之純化 的人參皂# 4 VII之](化合物處理時,於Sink運送穿越底 ' 室所測量之色胺酸吸收速率;及 圖5為線形圖,係顯示以經選擇濃度之純化的人參皂苷一 式v 11之K化合物處理Cac〇2單層之葉酸吸收速率。 3230 1317280 0, 1 M CK control group 0. 1 M Rbi -763 (L±_3. 206 !·7210 + 0> 1611 0. 0320 148.55 100 _ 108.72 t Control group 0. 1 M Rhi 7210 ± 0.1611 453 L 7210 ± 0.1611 —〇78Q ^ Π 1^/1 100 „ 49.36 ; Control group 0. 1 M Rgi 100 _ _ 62.64 4 Conclusion Folic acid intake can be used to extract 7 ginseng soap from Sanqi ginseng | Factory includes Formula I The version, the Rgi of the formula II, the CK of the formula vn or the rib 1 of the formula 。. The example above describes the regulation of nutrient absorption of colorectal cancer cells, but it should be understood that the invention is not < limited thereto. The cells of the gut cells and the gastrointestinal system have similar nutrient transporters! These cells are also expected to benefit from the regulatory utility of the ginsenoside compounds proposed by the present invention. Moreover, the ginsenosides of the present invention are in addition to glucose and In addition to its regulatory role in folate absorption, it can also be used to regulate the absorption of nutrients (including vitamins, amino acids, hormones, growth factors, and other important elements of cellular metabolism). Furthermore, the nutrients described in the specific examples Absorption test Tests and nutrient uptake tests can be performed interchangeably for assessing and evaluating the regulatory effects of the purified ginsenosides of the present invention on the absorption of personal nutrients. Those skilled in the art should understand that they do not detract from their broad inventive concepts. The above specific examples are subject to change. It is to be understood that the invention is not limited to the specific embodiments disclosed herein, but it is intended that such modifications be included in the invention as defined by the appended claims 31 1317280 [Simple Description of the Drawings] When combining the attached drawings and the responsibilities, the above-mentioned inventions will be better understood in the following embodiments. The invention is illustrated by the seven/τ^ washing. For purposes of the present invention, as shown in the specific examples of the drawings, 苴 is a description of the preferred embodiment, but it should be understood that the invention is not limited to the precise arrangements and tools shown. Thai $ map, showing the rate of glucose absorption measured when transported through the bottom chamber when Caco2 monolayer cells are treated with a selected concentration of ginseng soap team; Shows the glucose uptake rate measured by the Sink transport across the bottom chamber when the Caco2 monolayer is treated with a selected concentration of 11 ginseng saponin Rgl; Figure 3 is a line graph showing when the Caco2 monolayer is selected Concentration formula! j Purified ginseng soap Rgl treatment, the rate of arginine absorption measured by Sink transport across the bottom chamber; > Figure 4 is a line graph showing the Cac〇2 monolayer at selected concentrations Purified ginseng soap #4 VII] (the rate of tryptophan absorption measured in the Sink transport across the bottom chamber during compound treatment; and Figure 5 is a line graph showing the purified ginsenoside at a selected concentration. The K compound of 11 treated the fac acid absorption rate of the Cac〇2 monolayer. 32

Claims (1)

1317280 1 第〇95141624號專利申請寮 無畫線之申諳專利範圍替換百f站年8 十、申請專利範圍: 1. 一種調節受試者體内營養物質吸收之方法,其包含浐 予有效置由三七參(Fa贿⑽咖㈣叹)純化之人 參矣普化合物’用於調節運送營養物質穿越受試者之 腸道細胞,但不包括葡萄糖。1317280 1 Patent application No. 95116624 No application for patents, no patent line, no patent line, no replacement for 100 f station year, 10, application patent scope: 1. A method for regulating the absorption of nutrients in a subject, which includes effective placement The ginseng compound used by Sanqishen (Fa bribe (10) coffee (four) sighs) is used to regulate the transport of nutrients through the intestinal cells of the subject, but does not include glucose. 2 ·如清求項1之方法 組成之群中選出· 其中該人參皂苷化合物係由下列2 · Select the group consisting of the method of claim 1 · The ginsenoside compound is selected from the following 式I之人參皂苷Rbi,Ginsenoside Rbi of formula I, 式 苷 Rgi, 1317280Glycoside Rgi, 1317280 CC 式 式V之人參皂苷R] hoh2c, HOGinsenoside R] hoh2c, HO HOHO formula 式VII之人參皂苷κ 1317280Ginsenoside κ 1317280 of formula VII 式VIII之人參皂苷F! hoh2c. 6,Ginsenoside F of formula VIII F! hoh2c. ί 10 8 3 5 710 10 8 3 5 7 OH 式 VIII 式III之人參皂苷Rh!, 1317280OH Formula VIII Ginsenoside Rh of Formula III, 1317280 求員1之方法,其中該營養物質為胺基酸或維生 素。 4.如晴求項3之方法,其中該胺基酸為精胺酸或色胺酸。 5·如請求項3之方法,其中該維生素為葉酸。 1317280 6. #提南雙試者體内營養物質吸收之方法,其包含投 予有效1由二七參(尸α«αχ «oiogz.wsewg )純化之人參 息皆化合物之步驟,用於促進運送營養物質,但不包 括葡萄糖,穿越受試者之腸道細胞。 rj ’如睛求項6之方法,其中該營養物質為胺基酸或維生 素。 8_如請求項7之方法,其中該胺基酸為精胺酸或色胺酸。 9·如凊求項7或8之方法,其中該營養物質為精胺酸。 10. 如請求項9之方法,其中該精胺酸之吸收係藉由投 予浪度從〇· 001至5//M之人參皂苷化合物來促進運 送精胺酸穿越受試者之腸道細胞而得到提高。 11. 如請求項1 〇之方法,其中該人參皂苷化合物係包括 式1之人參皂苷Rbi、式II之人參皂苷Rgl、式VII 之化合物K、式III之人參皂苷Rh!、式VIII之人參 皂苦F,或式IX之20(s) —原人參三醇。 12. 如請求項7或8之方法,其中該營養物質為色胺酸。 )3.如請求項12之方法,該色胺酸之吸收係藉由投予濃 度從〇. 001至5#M之人參皂苷化合物來促進運送色 胺酸穿越受試者之腸道細胞而得到提高。 如請求項13之方法,其中該人參皂苷化合物係包括 式VII之化合物κ或式II之人參皂芽Rgi。 15.如請求項7之方法,其中該營養物質為葉酸。 5 1317280 1 6.如請求項15之方法,其中該葉酸之吸收係藉由投予 漠度從〇· 〇〇1至5以Μ之人參皂苷化合物來促進運送 葉酸穿越受試者之腸道細胞而得到提高。 1 7.如请求項16之方法,其中該人參皂苷化合物係包括 式νΠ之化合物Κ或式I之人參皂苷Rbi。 18_ —種抑制受試者體内營養物質吸收之方法,其包含 才又予有效量由三七參(尸純化之 人參皂苷化合物之步驟,用於減緩運送營養物質穿 越受試者之腸道細胞,但不包括葡萄糖。 19. 如請求項18之方法,其中該營養物質為維生素。 20. 如請求項19之方法,其中該營養物質為葉酸。 •如明求項2 0之方法,其中該葉酸之吸收係藉由投予 濃度從0.001至5# Μ之人參皂苷化合物來減緩運送 葉酸穿越受試者之腸道細胞而得到抑制。 22.如請求項21之方法,其中該人參皂苷化合物係包括 式Π之人參皂苷Rgl或式III之人參皂普Rh。 6 1317280 ; ♦ -1—*、圖式: 〇r/^(ί〇^Ύ 告本jThe method of claim 1, wherein the nutrient is an amino acid or a vitamin. 4. The method of claim 3, wherein the amino acid is arginine or tryptophan. 5. The method of claim 3, wherein the vitamin is folic acid. 1317280 6. #Method for the absorption of nutrients in the double tester, which comprises the step of administering a human ginseng compound purified by the ginseng α«αχ «oiogz.wsewg for promoting transportation Nutrients, but not glucose, traverse the intestinal cells of the subject. Rj '. The method of claim 6, wherein the nutrient is an amino acid or a vitamin. 8) The method of claim 7, wherein the amino acid is arginine or tryptophan. 9. The method of claim 7 or 8, wherein the nutrient is arginine. 10. The method of claim 9, wherein the absorption of the arginine is to facilitate delivery of arginine across the intestinal cells of the subject by administering a ginsenoside compound having a wave duration from 〇·001 to 5//M. And it is improved. 11. The method of claim 1, wherein the ginsenoside compound comprises ginsenoside Rbi of formula 1, ginsenoside Rgl of formula II, compound K of formula VII, ginsenoside Rh? of formula III, ginseng soap of formula VIII Bitter F, or 20(s) of formula IX - protopanaxatriol. 12. The method of claim 7 or 8, wherein the nutrient is tryptophan. 3. The method of claim 12, wherein the absorption of the tryptophan is obtained by administering a ginsenoside compound having a concentration from 〇. 001 to 5#M to facilitate delivery of the tryptophan acid through the intestinal cells of the subject. improve. The method of claim 13, wherein the ginsenoside compound comprises the compound κ of the formula VII or the ginseng bud RGI of the formula II. 15. The method of claim 7, wherein the nutrient is folic acid. 5. The method of claim 15, wherein the absorption of the folic acid promotes transport of folic acid across the intestinal cells of the subject by administering a ginsenoside compound in which the indifference is from 〇·〇〇1 to 5 And it is improved. The method of claim 16, wherein the ginsenoside compound comprises a compound of the formula νΠ or a ginsenoside Rbi of the formula I. 18_ A method for inhibiting the absorption of nutrients in a subject, comprising the step of administering an effective amount of ginseng saponin compound (the ginseng-purified ginsenoside compound) for slowing the transport of nutrients through the intestinal cells of the subject 19. The method of claim 18, wherein the nutrient is a vitamin. 20. The method of claim 19, wherein the nutrient is folic acid. The absorption of folic acid is inhibited by administering a ginsenoside compound having a concentration of from 0.001 to 5# to slow the transport of folic acid across the intestinal cells of the subject. 22. The method of claim 21, wherein the ginsenoside compound is Including ginsenoside Rgl of formula 人 or ginsenoside Rh of formula III. 6 1317280 ; ♦ -1—*, schema: 〇r/^(ί〇^Ύ 告本j '月u:'月u: 對照組 速率 =2.1814 ± 0.0584 μΜ/min Rbl(5 μΜ) 速率 = 3.5732 ±0.4504 μΜ/min Rbl (1 μΜ) 速率 -3.4250 ±0.4805 μΜ/min Rb 1(0.1 μΜ) 速率 ^=2.8107 ±0.1982 μΜ/min Rbl (0.01 μΜ) 速率 =2.2306 ± 0.1034 μΜ/min 1317280Control rate = 2.1814 ± 0.0584 μΜ / min Rbl (5 μΜ) Rate = 3.5732 ± 0.4504 μΜ / min Rbl (1 μΜ) Rate - 3.4250 ± 0.4805 μΜ / min Rb 1 (0.1 μΜ) Rate ^ = 2.8107 ± 0.1982 μΜ / Min Rbl (0.01 μΜ) rate = 2.2306 ± 0.1034 μΜ/min 1317280 對照組 速率=2.1814 士 0.0584 nniol/min Rgl (5 μΜ) 速率 Rgl(lpM) 速率 Rgl (0.1 μΜ) 速率 Rgl (0.01 μΜ)速率 1.7171 ± 0.1525 nmol/min 2.1089 ±0.2097 nmol/min 1.2763 ± 0.1907 nmol/min 1.1317 ± 0.1299 nmol/min •1317280Control rate = 2.1814 ± 0.0584 nniol / min Rgl (5 μΜ) Rate Rgl (lpM) Rate Rgl (0.1 μΜ) Rate Rgl (0.01 μΜ) Rate 1.7171 ± 0.1525 nmol/min 2.1089 ± 0.2097 nmol/min 1.2763 ± 0.1907 nmol/ Min 1.1317 ± 0.1299 nmol/min • 1317280 Ο 10 20 30 40 50Ο 10 20 30 40 50 時間(分鐘) 對照組 速率 1 μΜ Rgl 速率 0.1 pMRgl 速率 0.01 μΜ Rgl 速率 0.001 μΜ Rgl 速率 10,6855 ± 0.2523 nmol/min 18.3265 ± 0.8965 nmol/min 22.5370 ± 0.8912 nmol/min 13.5583 ± 1.1940 nmol/min 9.8264 土 0.7737 nmol/min 1317280Time (minutes) Control rate 1 μΜ Rgl rate 0.1 pMRgl rate 0.01 μΜ Rgl rate 0.001 μΜ Rgl rate 10,6855 ± 0.2523 nmol/min 18.3265 ± 0.8965 nmol/min 22.5370 ± 0.8912 nmol/min 13.5583 ± 1.1940 nmol/min 9.8264 0.7737 nmol/min 1317280 0.1 μΜ CK 速率=18.050 ± 0.5557 nmol/min 0.01 μΜ CK 速率=13.050 ± 0.5655 nmol/min 0.001 μΜ CK 速率=11.890 ± 0.5811 nmol/min 1317280 (M-mls 轵w/wMik 倒)_婪盏餡擁0.1 μΜ CK rate=18.050 ± 0.5557 nmol/min 0.01 μΜ CK rate=13.050 ± 0.5655 nmol/min 0.001 μΜ CK rate=11.890 ± 0.5811 nmol/min 1317280 (M-mls 轵w/wMik inverted)_婪盏Stuffed 對照組 1.8600 士 2.2480 pmol/mg 蛋白質/min 0.1 μΜ CK 2.7630 士 3.206 pmol/mg protein/minControl group 1.8600 ± 2.2480 pmol / mg protein / min 0.1 μΜ CK 2.7630 ± 3.206 pmol / mg protein / min
TW95141624A 2006-06-23 2006-11-10 Method for regulating nutrient absorption with ginsenosides TWI317280B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/426,064 US20060293255A1 (en) 2005-06-23 2006-06-23 Method for regulating nutrient absorption with ginsenosides

Publications (2)

Publication Number Publication Date
TW200800231A TW200800231A (en) 2008-01-01
TWI317280B true TWI317280B (en) 2009-11-21

Family

ID=44764745

Family Applications (1)

Application Number Title Priority Date Filing Date
TW95141624A TWI317280B (en) 2006-06-23 2006-11-10 Method for regulating nutrient absorption with ginsenosides

Country Status (1)

Country Link
TW (1) TWI317280B (en)

Also Published As

Publication number Publication date
TW200800231A (en) 2008-01-01

Similar Documents

Publication Publication Date Title
US20060293255A1 (en) Method for regulating nutrient absorption with ginsenosides
JP5593305B2 (en) Pharmaceutical compositions and polya extracts useful for promoting nutrient absorption
ES2543278T3 (en) Preparation procedure new processed ginseng or an extract thereof, whose normally minimal ginsenoside content is increased
KR100864455B1 (en) A Composition comprising the extract of complex herb improving Liver Cirrhosis, cytotoxicity and liver injury for preventing and treating of liver disease
KR20100124519A (en) Compositions containing green tea extracts
CN107106580A (en) The composition for the treatment of cancer stem cell
CN102549153A (en) Prophylactic and/or therapeutic agent for metabolic syndrome
US20120196817A1 (en) Method for enhancing nutrient absorption with astragalosides
US20120245343A1 (en) Arginine derivatives or salts thereof exhibiting the effects of improving sexual function, composition for improving sexual function comprising same, and method for preparing same
CN110251524A (en) The preparation method of compound lobetyolin (Lobetyolin) and the new application in drug and health care product
US20090181904A1 (en) Method for regulating nutrient absorption with ginsenosides
CN101228953B (en) Organic Se-rich lucid ganoderma healthy product and preparing method thereof
TWI441640B (en) Pharmaceutical composition and extract of poria for enhancing uptake of nutrients
CN106008613B (en) The unsaturated type mannuronic acid oligosaccharide of non reducing end and the composition comprising it as effective component
TWI317280B (en) Method for regulating nutrient absorption with ginsenosides
US9445624B2 (en) Anti-fatigue composition of plant material and preparation method, use and products thereof
CN111840425A (en) Traditional Chinese medicine composition for treating diabetic nephropathy and application thereof
KR101537856B1 (en) A pharmaceutical composition for preventing and treating nonalcoholic fatty liver disease comprising extraction fraction with enhanced gincenoside rb1 from panax ginseng as an active ingredient
CN107537028B (en) Formula for simultaneously assisting in reducing blood sugar and blood pressure and preparation method thereof
CN103182004B (en) Containing tealeaves, camellia and tea seed extract, for preventing or improving the composition of metabolic syndrome
CN111759952A (en) Application of dendrobe extract in preparation of drugs for regulating cholesterol metabolism
CN111773324A (en) Application of fresh dendrobium aqueous extract in preparing medicine for treating metabolic diseases
KR100895500B1 (en) Composition for the prevention and treatment of fatty liver diseases containing honokiol as an active ingredient
CN105250337A (en) Application of longitudinal stripe xylaria
Gim et al. Antioxidant effect of tianwang buxin pills a traditional Chinese medicine formula: double-blind, randomized controlled trial

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees